AZTRAzitra, Inc.

NYSE azitrainc.com


$ 0.10 $ -0.04 (-30.15 %)    

Friday, 28-Jun-2024 15:58:43 EDT
QQQ $ 479.98 $ -2.50 (-0.52 %)
DIA $ 391.11 $ -0.43 (-0.11 %)
SPY $ 544.70 $ -2.15 (-0.39 %)
TLT $ 91.77 $ -1.74 (-1.86 %)
GLD $ 215.03 $ 0.02 (0.01 %)
$ 0.0922
$ 0.10
$ 0.10 x 100
$ 0.00 x 0
$ 0.10 - $ 0.12
$ 0.09 - $ 4.33
3,365,822
na
62,027
$ 1.09
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-15-2024 12-31-2023 10-K
3 11-14-2023 09-30-2023 10-Q
4 08-14-2023 06-30-2023 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 azitra-announces-1-for-30-reverse-stock-split-will-become-effective-on-july-1-2024

Common Stock Will Begin Trading on a Split-Adjusted Basis on July 1, 2024

 azitra-received-notice-of-allowance-for-us-patent-application-titled-therapeutic-treatment-of-skin-disease-with-recombinant-commensal-skin-microorganisms

https://patentcenter.uspto.gov/applications/16890552/ifw/docs

 azitra-presents-preclinical-data-from-atr-04-at-society-of-investigative-dermatology-annual-meeting

ATR-04 is in development for epidermal growth factor receptor inhibitor (EGFRi)-induced dermal toxicity, which affects approxim...

 azitra-reports-preclinical-data-of-atr-12-and-clinical-design-on-netherton-syndrome-at-asgct-annual-meeting

ATR-12 has nanomolar inhibition of key protease in vitro that drives Netherton syndromeTopical application of ATR-12 to ex vivo...

 azitra-inc-announces-preclinical-data-from-the-cos-platform-and-pipeline-on-friday-may-10-2024-in-two-oral-sessions-entitled-engineered-staphylococcus-epidermidis-as-a-protein-delivery-system-for-treating-skin-diseases-and-staphylococcus-epidermidis-strain-expressing-lekti-d6-atr12-351-for-netherton-syndrome

Azitra will present two oral presentations at ASGCT (American Society of Gene and Cell Therapy) Baltimore, MD, May 7-11, 2024 r...

 silo-pharma-and-3-other-stocks-under-5-insiders-are-buying

The Dow Jones index closed lower by over 200 points on Monday. When insiders purchase or sell shares, it indicates their confid...

 azitra-inc-announces-fy23-eps-183-vs-1274-yoy-revenue-686k-vs-284k-yoy

Financial Results for the Year Ended December 31, 2023 Service Revenue – Related Party: The Company generated $0.7 million o...